- Shares of Zogenix (ZGNX) currently trade down 10% on double normal volume in response to yesterday's post close earnings report.
- Its recently-approved opioid drug, Zohydro, is controversial due to its perceived abuse potential.
- The company did not provide revenue guidance for 2014. It did disclose that it expects R&D and SG&A expenses to come in at $110M - $120M.
- Press release